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ZEBRAFISH MODEL OF MLL-REARRANGED ACUTE MYELOID LEUKEMIA
ALEX BELT, SETH J. COREY, STEVEN GRANT, ROBERT M. TOMBES, AND SARAH C. ROTHSCHILD
Virginia Commonwealth University, Richmond, VA

Abstract
Acute myeloid leukemia (AML) is the second most common type of leukemia and accounts for
80% of adult acute leukemia cases, and is characterized by the accumulation of poorly or undifferentiated myeloid blast cells. Furthermore, AML patients harboring a chromosomal
rearrangement involving Multiple Lineage Leukemia (MLL) that results in the expression of an MLL
fusion protein exhibit far worse prognoses than patients without. In recent years, Danio rerio
(zebrafish) has emerged as a powerful model organism for investigating human blood malignancies
due to the conservation of hematopoiesis between humans and zebrafish. The first objective of
this study was to develop a transient transgenic AML model in zebrafish, and the second objective
was to determine if co-treatment with two medications currently in human trials for AML,
Venetoclax and Flavopiridol, would be more effective than using either drug individually. In order to
develop a transient transgenic AML model, we first developed a DNA construct encoding a known
mixed lineage leukemia (MLL) fusion protein associated with human AML, MLL-ENL, driven by the
zebrafish lysozyme C (lyz) promoter, which drives myeloid specific expression in zebrafish. We then
microinjected single-cell zebrafish embryos with DNA encoding lyz driven MLL-ENL along with
transposase mRNA to facilitate the genomic integration of MLL-ENL. Injected embryos were first
tested for MLL-ENL expression, and subsequently tested for AML phenotypic characteristics, via
whole mount in-situ hybridization (WISH) at 48 and 72 hours post fertilization (hpf). First, WISH
analysis utilizing a human MLL riboprobe verified MLL-ENL expression in injected embryos, and
WISH analysis utilizing the same MLL riboprobe revealed an expansion and clustering of MLL
positive cells in injected embryos, characteristic of an AML phenotype. We then characterized the
cell type expressing MLL-ENL by conducting WISH with other myeloid marker probes, and also
characterized the AML phenotype by showing overexpression of Bcl2 and Cdk9 in MLL-ENL
expressing embryos, both of which are overexpressed in human AML. Finally, embryos injected
with MLL-ENL DNA were treated with either DMSO (vehicle), 200 nano-Molar (nM) Venetoclax,
200 nM Flavopiridol, or 200 nM Venetoclax and 200 nM Flavopiridol from 24 hpf to 72 hpf. MLL
WISH analysis of injected and treated embryos revealed a reduction in MLL positive cells in both
Venetoclax treated embryos and Flavopiridol treated embryos, and an even greater reduction in
MLL positive cells in embryos treated with both Venetoclax and Flavopiridol, compared to controls.
Although further analysis is required to be confident, this data suggests that we successfully
developed an AML transient transgenic model in zebrafish. Furthermore, these data suggest that
Venetoclax and Flavopiridol co-treatment could yield better outcomes for AML patients than
treatment with either drug individually.

MLL+ Cell Expansion in Lyz Driven MLL-ENL
Embryos

Spi1+ Cell Expansion in Lyz Driven MLL-ENL Embryos

Venetoclax and Flavopiridol Dose Response

Figure 4. Venetoclax and flavopiridol treatment
does not affect embryogenesis or myeloid
development at low concentrations. Dr. Steven
Grant provided our lab with Venetoclax and
Flavopiridol to perform studies on MLL- ENL
injected Embryos in conjunction with studies
in his lab. To determine if drug treatment altered
embryogenesis or myeloid development
in zebrafish embryos we treated wild type
embryos with varying concentrations from 0
nM- 500 nM of Venetoclax and Flavopiridol,
and conducted WISH analysis with an lyz
probe. Lyz+ cell counts in the CHT were reduced
with treatment of either drug at 500 nM, but
no significant difference was observed with
100 nM treatment.

Venetoclax and Flavopiridol Co-Treatment Inhibits MLLENL Cell Expansion
Figure 2. Lyz, mpo, and spi1 expression in MLL-ENL expressing embryos. Embryos were fixed at 48 hpf and
WISH was conducted using lyz, mpo, and spi1 riboprobes. While there is a slight increase in lyz and mpo
expressing cells in the CHT of MLL-ENL expressing embryos compared to controls, a clustered expansion on
the yolk sac is not observed. However, a clustered expansion of spi1 expressing cells can be observed on the
yolk sac of MLL-ENL expressing embryos, suggesting that the cells expressing MLL-ENL are spi1+ and not lyz+
or mpo+.

Bcl2+ and Cdk9+ Cell Expansion in Lyz Driven MLLENL Embryos

Figure 5. Venetoclax and Flavopiridol co-treatment results in a greater reduction in mll positive cell expansion
than either individual treatment. Before fixing at 72 hpf and conducting subsequent WISH analysis, MLL-ENL
injected embryos were treated with DMSO, 200 nM Venetoclax, 200 nM Flavopiridol, or 200 nM of both drugs
beginning at 24 hpf. Embryos were fixed at 72 hpf, WISH analysis was performed using a human MLL probe,
MLL+ cells on the yolk were counted. In a separate experiment, an lyz probe was used to assay lyz+ cell counts in
the CHT of MLL-ENL injected embryos after one of the 4 treatments listed above.
Figure 1. MLL-ENL expression in injected embryos. At 72 hpf, embryos were fixed, WISH analysis was
conducted, and positive cell counts were taken on MLL-ENL injected embryos using human MLL and
zebrafish lyz probes, with uninjected embryos used as controls. In injected embryos, human MLL expression
can be observed in clusters of cells on the yolk, and endogenous lyz expression is not significantly reduced in
the caudal hematopoietic tissue (CHT), where lyz is predominantly expressed at 72 hpf, compared to controls.
Furthermore, the average heart rate of injected embryos was not significantly different than controls,
suggesting that the increased number of of MLL positive cells on the yolk of injected embryos is not due to
insufficient circulation (data now shown).
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Figure 3. Bcl2 and cdk9 overexpression in MLL-ENL expressing embryos. As both BCL2 and CDK9 are
overexpressed in human AML, we designed bcl2 and cdk9 riboprobes to further characterize the AML
phenotype of our model. Conducting WISH analysis at 48 hpf using these probes revealed a clustered
expansion of both bcl2 and cdk9 expressing cells on the yolk sac of MLL-ENL expressing embryos. This
further suggests that the expression of MLL-ENL induces an AML phenotype in zebrafish.
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